Literature DB >> 11021551

A comparison of short wavelength automated perimetry with frequency doubling perimetry for the early detection of visual field loss in ocular hypertension.

J Landers1, I Goldberg, S Graham.   

Abstract

BACKGROUND: Achromatic automated perimetry (AAP) is limited in its ability to detect very early visual field loss in ocular hypertensive patients. Tests targeting axons that are selectively damaged, or have low redundancy, may detect visual field losses before they are seen on AAP. It has been claimed that short wavelength automated perimetry (SWAP) and frequency doubling perimetry (FDP) are two tests that provide early detection.
METHODS: Patients (n = 62) were selected on the basis that they had raised intraocular pressure but normal visual fields detected by AAP. A SWAP and an FDP was performed on each of the patients and the results compared. Fields were scored as either normal or abnormal based on criteria used in previous studies.
RESULTS: On comparing FDP with SWAP as the 'gold standard', a sensitivity of 88.9% and a specificity of 96.2% was found, showing a high concordance between the two tests.
CONCLUSION: These results suggest that as SWAP may be predictive of AAP visual field loss, FDP may be similarly predictive.

Entities:  

Mesh:

Year:  2000        PMID: 11021551     DOI: 10.1046/j.1442-9071.2000.00318.x

Source DB:  PubMed          Journal:  Clin Exp Ophthalmol        ISSN: 1442-6404            Impact factor:   4.207


  10 in total

1.  Short wavelength automated perimetry and tamoxifen use.

Authors:  A Eisner; D F Austin; J R Samples
Journal:  Br J Ophthalmol       Date:  2004-01       Impact factor: 4.638

2.  A comparison of perimetric results with the Medmont and Humphrey perimeters.

Authors:  J Landers; A Sharma; I Goldberg; S Graham
Journal:  Br J Ophthalmol       Date:  2003-06       Impact factor: 4.638

3.  Residual and Dynamic Range of Retinal Nerve Fiber Layer Thickness in Glaucoma: Comparison of Three OCT Platforms.

Authors:  Jean-Claude Mwanza; Hanna Y Kim; Donald L Budenz; Joshua L Warren; Michael Margolis; Scott D Lawrence; Pooja D Jani; Garrett S Thompson; Richard K Lee
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-10       Impact factor: 4.799

4.  Comparison between frequency-doubling technology perimetry and standard automated perimetry in early glaucoma.

Authors:  Seong Ah Kim; Chan Kee Park; Hae-Young Lopilly Park
Journal:  Sci Rep       Date:  2022-06-17       Impact factor: 4.996

5.  Predicting progression of glaucoma from rates of frequency doubling technology perimetry change.

Authors:  Daniel Meira-Freitas; Andrew J Tatham; Renato Lisboa; Tung-Mei Kuang; Linda M Zangwill; Robert N Weinreb; Christopher A Girkin; Jeffrey M Liebmann; Felipe A Medeiros
Journal:  Ophthalmology       Date:  2013-11-26       Impact factor: 12.079

6.  Prediction of future scotoma on conventional automated static perimetry using frequency doubling technology perimetry.

Authors:  S Kogure; Y Toda; S Tsukahara
Journal:  Br J Ophthalmol       Date:  2006-03       Impact factor: 4.638

7.  The association of office intraocular pressure fluctuation in ocular hypertension with frequency doubling technology perimetry abnormality.

Authors:  Volkan Dayanir; Sayime Aydin; Pinar Okyay
Journal:  Int Ophthalmol       Date:  2007-10-16       Impact factor: 2.031

8.  Frequency-doubling technology perimetry and multifocal visual evoked potential in glaucoma, suspected glaucoma, and control patients.

Authors:  Fabio N Kanadani; Paulo Aa Mello; Syril K Dorairaj; Tereza Cm Kanadani
Journal:  Clin Ophthalmol       Date:  2014-07-14

9.  Usefulness of frequency doubling technology perimetry 24-2 in glaucoma with parafoveal scotoma.

Authors:  Kyoung In Jung; Eun Kyoung Kim; Chan Kee Park
Journal:  Medicine (Baltimore)       Date:  2017-06       Impact factor: 1.817

10.  THE ROLE OF FREQUENCY DOUBLING TECHNOLOGY PERIMETRY IN EARLY DETECTION OF DIABETIC RETINOPATHY.

Authors:  Mario Bradvica; Dubravka Biuk; Ivanka Štenc Bradvica; Maja Vinković; Branimir Cerovski; Ivona Barać
Journal:  Acta Clin Croat       Date:  2020-03       Impact factor: 0.932

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.